The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Open accessAbstract
BACKGROUND: Prostate cancer (PCa) is the second most common disease among men worldwide. It is important to know survival outcomes and prognostic factors for this disease. Recruitment for the largest therapeutic randomised controlled trial in PCa--the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial (STAMPEDE)--includes men with newly diagnosed metastatic PCa who are commencing long-term androgen deprivation therapy (ADT); the control arm provides valuable data for a prospective cohort. OBJECTIVE: Describe survival outcomes, along with current treatment standards and factors associated with prognosis, to inform future trial design in this patient group. DESIGN, SETTING, AND PARTICIPANTS: STAMPEDE trial control arm comprising men newly diagnosed with M1 disease who were recruited between October 2005 and January 2014. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) and failure-free survival (FFS) were reported by primary disease characteristics using Kaplan-Meier methods. Hazard ratios and 95% confidence intervals (CIs) were derived from multivariate Cox models. RESULTS AND LIMITATIONS: A cohort of 917 men with newly diagnosed M1 disease was recruited to the control arm in the specified interval. Median follow-up was 20 mo. Median age at randomisation was 66 yr (interquartile range [IQR]: 61-71), and median prostate-specific antigen level was 112 ng/ml (IQR: 34-373). Most men (n=574; 62%) had bone-only metastases, whereas 237 (26%) had both bone and soft tissue metastases; soft tissue metastasis was found mainly in distant lymph nodes. There were 238 deaths, 202 (85%) from PCa. Median FFS was 11 mo; 2-yr FFS was 29% (95% CI, 25-33). Median OS was 42 mo; 2-yr OS was 72% (95% CI, 68-76). Survival time was influenced by performance status, age, Gleason score, and metastases distribution. Median survival after FFS event was 22 mo. Trial eligibility criteria meant men were younger and fitter than general PCa population. CONCLUSIONS: Survival remains disappointing in men presenting with M1 disease who are started on only long-term ADT, despite active treatments being available at first failure of ADT. Importantly, men with M1 disease now spend the majority of their remaining life in a state of castration-resistant relapse. PATIENT SUMMARY: Results from this control arm cohort found survival is relatively short and highly influenced by patient age, fitness, and where prostate cancer has spread in the body.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“Several new agents have been licensed for mCRPC since 2002, including therapies such as docetaxel [2,3], cabazitaxel [4], and abiraterone [5,7]; there are other new agents such as enzalutamide [6], radium-223 [8], and sipuleucel-T [9] with positive results but limited availability so far in this cohort.”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“Several new agents have been licensed for mCRPC since 2002, including therapies such as docetaxel [2,3], cabazitaxel [4], and abiraterone [5,7]; there are other new agents such as enzalutamide [6], radium-223 [8], and sipuleucel-T [9] with positive results but limited availability so far in this cohort.”
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“Several new agents have been licensed for mCRPC since 2002, including therapies such as docetaxel [2,3], cabazitaxel [4], and abiraterone [5,7]; there are other new agents such as enzalutamide [6], radium-223 [8], and sipuleucel-T [9] with positive results but limited availability so far in this cohort.”
Self-citationPetrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
Self-citationde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 744
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 674
Lipton, A., Fizazi, K., Stopeck, A. T., Henry, D. H., Brown, J. E., Yardley, D. A., Richardson, G. E., Siena, S., Maroto, P., Clemens, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.002 · Cited by 588
Hussain, M., Tangen, C. M., Higano, C., Schelhammer, P. F., Faulkner, J., Crawford, E. D., Wilding, G., Akdas, A., Small, E. J., Donnelly, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4246 · Cited by 505
Castration-Resistant Prostate Cancer: AUA Guideline
Cookson, M. S., Roth, B. J., Dahm, P., Engstrom, C., Freedland, S. J., Hussain, M., Lin, D. W., Lowrance, W. T., Murad, M. H., Oh, W. K., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.05.005 · Cited by 275
Dearnaley, D. P. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg038 · Cited by 234
Self-citationDalesio, O., VANTINTEREN, H., Denis, L., Schröder, F. H., Blumenstein, B. A., Godwin, J., & Peto, R. (1995) · The Lancet · Cited by 229
Dearnaley, D. P., Mason, M. D., Parmar, M. K., Sanders, K., & Sydes, M. R. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70201-3 · Cited by 204
Self-citationSpeeding up the Evaluation of New Agents in Cancer
Parmar, M., Barthel, F. M.-S., Sydes, M. R., Langley, R. E., Kaplan, R. S., Eisenhauer, E. A., Brady, M. F., James, N. D., Bookman, M. A., Swart, A. M., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn267 · Cited by 146
Self-citationBarocas, D. A., Mallin, K., Graves, A. J., Penson, D. F., Palis, B. E., Winchester, D. P., & Chang, S. S. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.06.075 · Cited by 126
Tangen, C. M., Hussain, M., Higano, C. S., Eisenberger, M. A., Small, E. J., Wilding, G., Donnelly, B. J., Schelhammer, P. F., Crawford, E. D., Vogelzang, N. J., et al. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.06.046 · Cited by 101
Attard, G., Sydes, M. R., Mason, M. D., Clarke, N. W., Aebersold, D. M., Bono, J. S. D., Dearnaley, D. P., Parker, C. C., Ritchie, A. W. S., Russell, J. M., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.038 · Cited by 70
Self-citationJames, N. D., Sydes, M. R., Clarke, N. W., Mason, M., Dearnaley, D. P., Anderson, J., Popert, R., Sanders, K., Morgan, R. C., Stansfeld, J., et al. (2008) · Clinical Oncology · doi:10.1016/j.clon.2008.07.002 · Cited by 58
Self-citationFred Saad, C., Chen, Y., Gleason, D. M., & Chin, J. L. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.022 · Cited by 51
Krauss, D. J., Hu, C., Bahary, J.-P., Souhami, L., Gore, E., Chafe, S., Leibenhaut, M. H., Narayan, S., Torres–Roca, J. F., Michalski, J. M., et al. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.03.017 · Cited by 36
Cited by
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Self-citationAbiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
Self-citationCornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Self-citation
Metadata
- Authors
- James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., De Bono, J. S., Gale, J., Hetherington, J., Hoskin, P. J., Jones, R. J., Laing, R., Lester, J. F., McLaren, D., Parker, C. C., Parmar, M. K. B., Ritchie, A. W. S., Russell, J. M., Strebel, R. T., Thalmann, G. N., Mason, M. D., & Sydes, M. R.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 67
- Issue
- 6
- Pages
- 1028-1038
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2168242827
- Cited by
- 425
- References
- 27
- FWCI
- 28.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.